1. Food and Drug Administration, HHS . International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 2005; 70: 61134–5.
2. fda.gov [homepage on the Internet]. E14 implementation working group: ICH E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs questions & answers (R1). [updated 2016 Mar 3
3. cited 2017 Jun 23]. Available from: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm323656.htm
4. Song S, Matsushima N, Lee J, Mendell J . Linear mixed-effects model of QTc prolongation for olmesartan medoxomil. J Clin Pharmacol 2016; 56: 96–100.
5. Vandemeulebroecke M, Lembcke J, Wiesinger H, Sittner W, Lindemann S . Assessment of QT(c)-prolonging potential of BX471 in healthy volunteers. A 'thorough QT study' following ICH E14 using various QT(c) correction methods. Br J Clin Pharmacol 2009; 68: 435–46.